The stock of Twist Bioscience Corporation (NASDAQ:TWST) increased by $0.6 on Friday to finish at $19.78, up 3.13 percent. The last five days have seen an average of 671,520 shares of common stock traded. 9 times new highs were reached in the current year, with a fall of -$4.03. The average number of shares traded over the last 20 days was 1,150,520, while the average volume over the last 50 days totaled 1,118,898.
TWST stock dropped -20.47% since last month. On 08/18/23, the company’s shares reached a one-month low of $18.23. The stock touched a high of $46.69 on 02/02/23, after rallying from a low of $11.46 in 52 weeks. The price of TWST stock has declined by -16.93% or -$4.03 this year, reaching a new high 9 times. Still, the stock price is down -57.64% from the 52-week high.
Insider Transactions
TWST stock investors should be aware that Twist Bioscience Corporation (TWST) stock had its last reported insider trading activity 110 days ago on May 10. On May 10, Cho Dennis acquired 10,000 shares at $13.20 each. This transaction resulted in the insider spending $132,000. On Feb 09, Starovasnik Melissa A. sold 1,732 shares at a price of US$26.45. After the transaction, the insider now owns 11,340 shares. Director JOHANNESSEN JAN had earlier sold 1,732 shares on Feb 09 for $26.45 a share. The transaction was completed for $45,820.
Valuation Metrics
Beta for the stock is 1.31. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 4.67, the price-to-book (PB) ratio of 1.72.
Financial Health
For the three months ended June 29, Twist Bioscience Corporation’s quick ratio was 5.60, while its current ratio was 6.10, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 38.60% percent. Twist Bioscience Corporation’s EBITDA margin for the year ended June 29 was -104.33%, whereas its operating margin stood at -93.20% for the same period. Based on annual data, it had gross profit of $84.23 million and revenue of $203.56 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TWST’s return on assets (ROA) during the last 12 months has been -23.70%. There was a -27.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -28.90%.
Earnings Surprise
According to Twist Bioscience Corporation’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $63.74 million, while revenues rose by 11.97% to $60.18 million. It was predicted that Twist Bioscience Corporation’s quarterly earnings would be -$1.01, but it ended up being -$1.14, beating the consensus by 11.40%. EBITDA was -$52.29 million for the quarter. At the end of Twist Bioscience Corporation’s most recent quarter ended June 29, its liabilities totaled 152.78 million, while its total debt was $93.03 million. Equity owned by shareholders amounts to $57.4 million.
Technical Picture
Here’s a quick look at Twist Bioscience Corporation’s (TWST) price momentum from a technical perspective. As of 25 August, the RSI 9-day stood at 41.87%, suggesting the stock is Neutral, with a 72.19% historical volatility rate.
The stochastic %K and %D were 26.78% and 25.57% respectively, while the average true range (ATR) was 1.29. Based on the 14-day stochastic reading of 29.25%, the RSI (14) reading is 43.41%. On the 9-day MACD Oscillator, the stock is at 0.10, and the 14-day reading is at -0.95.
Analyst Ratings
In its analyst report released on January 05, 2023, Scotiabank began covering Twist Bioscience Corporation (NASDAQ: TWST). The stock was rated as a Sector outperform by the brokerage firm. Analysts have assigned Twist Bioscience Corporation (TWST) an Overweight rating. TWST is a stock that is recommended for selling by 1 brokerage firm, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 2 rates it overweight and 5 others recommend it as a buy.
What is TWST’s price target for the next 12 months?
The current consensus forecast for the stock is between $19.00 and $33.00, with a median target price of $26.50. In analyzing these forecasts, the average price target given by analysts for Twist Bioscience Corporation (TWST) is $26.25.
